Could a cell injection free type 1 diabetics from insulin?
NCT ID NCT06731218
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage trial tests a new treatment called RGB-5088 for people with type 1 diabetes. It involves transplanting insulin-making cells under a muscle layer in the abdomen. The goal is to see if it is safe and if it can help patients control blood sugar without insulin shots. Only 10 people will take part in this first study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RGB-5088 islet cells
- What this could lead to
- If successful, this could point toward a way to reduce or eliminate insulin injections for people with type 1 diabetes.
- What could go wrong
- This is a very early Phase 1 trial with only 10 people. It is designed mainly to check safety, not yet to prove it works. Risks include side effects from the procedure or the cells not lasting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin First Center Hospital
RECRUITINGTianjin, Tianjin Municipality, 300000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- FitBit coaching may help amputees walk more after surgery
- Could a stress hormone be behind the hidden danger of low blood sugar?
- Can AI catch the leading cause of blindness before It's too late?
- Can a peptide tame type 1 diabetes?
- Does feeling stigmatized worsen life quality for men with low testosterone?
- Can community hospitals in zambia master severe disease care?